Integer (NYSE:ITGR) Hits New 52-Week High – Time to Buy?

Posted by Brenda Bartman on Jul 31st, 2026

Integer Holdings Corporation (NYSE:ITGR – Get Free Report) reached a new 52-week high on Friday . The company traded as high as $112.01 and last traded at $121.2250, with a volume of 263588 shares trading hands. The stock had previously closed at $100.86.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ITGR. Zacks Research upgraded Integer from a “strong sell” rating to a “hold” rating in a research note on Monday, July 20th. Citigroup boosted their price target on Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Piper Sandler restated an “overweight” rating and issued a $97.00 price objective (up from $87.00) on shares of Integer in a research report on Friday, May 1st. KeyCorp reaffirmed an “overweight” rating and set a $104.00 price objective on shares of Integer in a research note on Tuesday, July 21st. Finally, Truist Financial lifted their target price on shares of Integer from $97.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

Check Out Our Latest Analysis on Integer

Integer Stock Up 20.3%

The company has a market cap of $4.12 billion, a price-to-earnings ratio of 30.26, a PEG ratio of 2.38 and a beta of 0.64. The business has a fifty day moving average of $93.24 and a two-hundred day moving average of $88.72. The company has a current ratio of 3.75, a quick ratio of 2.38 and a debt-to-equity ratio of 0.77.

Integer (NYSE:ITGR – Get Free Report) last released its earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). Integer had a return on equity of 12.83% and a net margin of 7.64%.The company had revenue of $439.58 million for the quarter, compared to analysts’ expectations of $426.48 million. During the same period in the prior year, the firm earned $1.31 EPS. The firm’s revenue for the quarter was up .5% on a year-over-year basis. As a group, equities analysts anticipate that Integer Holdings Corporation will post 6.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Integer

Several large investors have recently bought and sold shares of the company. Heartland Advisors Inc. boosted its stake in shares of Integer by 506.8% in the fourth quarter. Heartland Advisors Inc. now owns 242,715 shares of the medical equipment provider’s stock worth $19,036,000 after acquiring an additional 202,715 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Integer during the fourth quarter worth $4,836,000. Jennison Associates LLC purchased a new stake in shares of Integer during the fourth quarter worth $1,036,000. Kestrel Investment Management Corp acquired a new stake in shares of Integer in the fourth quarter valued at about $5,933,000. Finally, William Blair Investment Management LLC lifted its stake in shares of Integer by 70.1% in the fourth quarter. William Blair Investment Management LLC now owns 468,377 shares of the medical equipment provider’s stock worth $36,735,000 after buying an additional 192,956 shares in the last quarter. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Integer Company Profile

(Get Free Report)

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.